Skip to site content

FDA Recommends Discussing Naloxone with All Patients Receiving Opioid Prescriptions

July 23, 2020


From 1999 to 2018, nearly 450,000 people died from an overdose involving any opioid, including prescription and illicit opioids. Opioids were involved in 46,802 deaths in 2018. The Food and Drug Administration (FDA) is encouraging health care professionals to raise awareness of the availability of naloxone when they are prescribing and dispensing opioid pain relievers or medicines to treat opioid use disorder (OUD).


FDA recommends discussing naloxone with all patients and/or their caregivers when prescribing opioid analgesics or medicines to treat opioid use disorder (OUD). Assess the potential need for patient or home access to naloxone, both when initiating and renewing treatment with opioid analgesics and medicines to treat OUD.

Discuss naloxone with all patients and caregivers when prescribing opioid analgesics or medications to treat OUD.

For more information, the full FDA Drug Safety Alert and other resources can be found on the FDA website Exit Disclaimer: You Are Leaving .

Report adverse events involving this or other medicines to the MedWatch program as recommended in the Indian Health Manual and include “IHS” in the reporter section (section G).

Instructions for reporting can be found online at the NPTC Pharmacovigilance website.